Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
Earth-Agent-Pro: Towards Real-World Full-Chain Earth Observation with Agents
arXiv:2609.12533v1 Announce Type: cross Abstract: Real-world Earth observation (EO) agents must translate high-level scientific questions into executable workflows to acquire observations, prepare data, perform domain computations, and derive conclusions from runtime evidence. Existing EO agents typically start from supplied observations, while benchmarks typically provide prepared inputs or candidate answers, leaving full-chain open-world EO execution largely untested. We present Earth-Agent-P
-
Molecular Therapy
-
In vivo-directed evolution identifies AAV-WM04 as a next-generation vector for potent and sustained hearing restoration in DFNB9
AAV-WM04, an AAV vector identified through in-vivo-directed screening in the adult cochlea, enables highly efficient and selective inner hair cell transduction. Dual-AAV delivery of OTOF using AAV-WM04 restores hearing in a DFNA9 deafness mouse model at low doses, highlighting its translational potential for gene therapy.
In vivo-directed evolution identifies AAV-WM04 as a next-generation vector for potent and sustained hearing restoration in DFNB9
-
Pulmonary nodule
-
The 2025 lung cancer landscape: advances in screening, molecular taxonomy and therapeutic strategy: a narrative review
Transl Lung Cancer Res. 2026 Mar 23;15(3):62. doi: 10.21037/tlcr-2025-1-1477. Epub 2026 Mar 18.ABSTRACTBACKGROUND AND OBJECTIVE: In 2025, lung cancer research advanced rapidly across the disease continuum, from population-level risk assessment and screening to mechanistic studies of early carcinogenesis and therapeutic innovation in perioperative and metastatic settings. A key shift moved beyond a smoking-centred paradigm toward a multidimensional risk framework reflecting the growing burden amo
The 2025 lung cancer landscape: advances in screening, molecular taxonomy and therapeutic strategy: a narrative review
Transl Lung Cancer Res. 2026 Mar 23;15(3):62. doi: 10.21037/tlcr-2025-1-1477. Epub 2026 Mar 18.
ABSTRACT
BACKGROUND AND OBJECTIVE: In 2025, lung cancer research advanced rapidly across the disease continuum, from population-level risk assessment and screening to mechanistic studies of early carcinogenesis and therapeutic innovation in perioperative and metastatic settings. A key shift moved beyond a smoking-centred paradigm toward a multidimensional risk framework reflecting the growing burden among never-smokers and the roles of air pollution, occupational exposures, and systemic metabolic-inflammatory states. This narrative review aims to synthesize influential 2025 evidence across prevention, diagnosis, treatment, and survivorship, and to identify convergent themes and translational gaps relevant to clinical practice and policy.
METHODS: We performed a narrative synthesis of influential lung cancer studies published in major international journals in 2025. Evidence was organized along a clinically oriented pathway spanning carcinogenesis and screening, precision diagnosis, treatment optimization in resectable and advanced disease, and survivorship, emphasizing practice-informing trials, high-impact translational research, and implementation-relevant technologies.
KEY CONTENT AND FINDINGS: Lineage tracing, single-cell and spatial omics, and evolutionary inference refined concepts of field cancerization, clonal selection, and copy-number-driven fitness. In small-cell lung cancer, evidence further supported neuronal coupling and synapse-like programs as potentially tractable vulnerabilities. Clinically, low-dose computed tomography (CT) strategies and data-informed nodule thresholds aimed to balance under-detection against over-surveillance harms. In diagnostics, artificial intelligence (AI) models increasingly inferred molecular features from routine histopathology ("virtual molecular testing") and should be regarded as decision support requiring prospective validation, population calibration, and explicit failure-mode reporting. Multimodal approaches integrating imaging with circulating tumor DNA (ctDNA) improved feasibility in tissue-limited settings, but clinical utility remains contingent on assay standardization and pathway-level implementation. In resectable disease, longer follow-up consolidated neoadjuvant chemo-immunotherapy for selected patients, while ctDNA kinetics emerged as a candidate biomarker for response-adaptive escalation and de-escalation. In advanced non-small cell lung cancer (NSCLC), phase III evidence for antibody-drug conjugates and bispecific antibodies began reshaping sequencing, while highlighting challenges in toxicity, access, affordability, and immature overall survival in several programs.
CONCLUSIONS: The 2025 landscape reflects coordinated progress in risk conceptualization, biology, diagnostics, and therapeutics, yet gaps in validation, standardization, and real-world deliverability persist. Priorities include prospective evaluation of AI- and ctDNA-enabled pathways, toxicity-informed sequencing, and equitable implementation aligned with health-system capacity.
PMID:41982682 | PMC:PMC13071762 | DOI:10.21037/tlcr-2025-1-1477
-
Omics In Lung
-
Integrative fragmentomic and mutational signature profile of plasma cfDNA for early lung cancer detection
NPJ Precis Oncol. 2026 Apr 15. doi: 10.1038/s41698-026-01416-y. Online ahead of print.ABSTRACTDetecting lung cancer effectively in the general population is essential for optimizing treatment outcomes and improving the 5-year survival rate. While low-dose computed tomography (LDCT) is the current standard, it has limitations in broader populations. We developed a blood-based multi-omics model using whole-genome cell-free DNA (cfDNA) features to distinguish lung cancer from non-cancer individuals
Integrative fragmentomic and mutational signature profile of plasma cfDNA for early lung cancer detection
NPJ Precis Oncol. 2026 Apr 15. doi: 10.1038/s41698-026-01416-y. Online ahead of print.
ABSTRACT
Detecting lung cancer effectively in the general population is essential for optimizing treatment outcomes and improving the 5-year survival rate. While low-dose computed tomography (LDCT) is the current standard, it has limitations in broader populations. We developed a blood-based multi-omics model using whole-genome cell-free DNA (cfDNA) features to distinguish lung cancer from non-cancer individuals. This study included 1600 patients and an equal number of non-cancer controls, divided into training and validation cohorts. The model achieved an area under the curve (AUC) of 95.59% for the training cohort and 95.74% for the validation cohort. The model consistently performed well across various cancer stages and histological subtypes. To further validate the performance of the model, an external validation cohort was utilized. Notably, it also effectively differentiated non-cancer samples from cancer samples in the external validation cohort, with 85.9% sensitivity and 94.78% specificity. Importantly, in simulated population screenings, our ctDNA assay outperformed both LDCT and a previously established method. This suggests its potential utility in wider lung cancer screening programs, possibly complementing the LDCT approach. In conclusion, our ctDNA assay emerges as a promising and highly sensitive tool for the early detection and categorization of lung cancer.
PMID:41986614 | DOI:10.1038/s41698-026-01416-y
-
cs.AI, q-bio.NC updates on arXiv.org
-
MoltNet: Understanding Social Behavior of AI Agents in the Agent-Native MoltBook
arXiv:2602.13458v2 Announce Type: replace-cross Abstract: Large-scale communities of AI agents are becoming increasingly prevalent, creating new environments for agent-agent social interaction. Prior work has examined multi-agent behavior primarily in controlled or small-scale settings, limiting our understanding of emergent social dynamics at scale. The recent emergence of MoltBook, a social networking platform designed explicitly for AI agents, presents a unique opportunity to study whether a
MoltNet: Understanding Social Behavior of AI Agents in the Agent-Native MoltBook
-
cs.AI, q-bio.NC updates on arXiv.org
-
KARL: Knowledge-Aware Reasoning and Reinforcement Learning for Knowledge-Intensive Visual Grounding
arXiv:2503.12797v3 Announce Type: replace-cross Abstract: Knowledge-Intensive Visual Grounding (KVG) requires models to localize objects using fine-grained, domain-specific entity names rather than generic referring expressions. Although Multimodal Large Language Models (MLLMs) possess rich entity knowledge and strong generic grounding capabilities, they often fail to effectively utilize such knowledge when grounding specialized concepts, revealing a knowledge-grounding gap between internal kno
KARL: Knowledge-Aware Reasoning and Reinforcement Learning for Knowledge-Intensive Visual Grounding
-
cs.AI, q-bio.NC updates on arXiv.org
-
Through the Lens of Contrast: Self-Improving Visual Reasoning in VLMs
arXiv:2603.02556v1 Announce Type: cross Abstract: Reasoning has emerged as a key capability of large language models. In linguistic tasks, this capability can be enhanced by self-improving techniques that refine reasoning paths for subsequent finetuning. However, extending these language-based self-improving approaches to vision language models (VLMs) presents a unique challenge:~visual hallucinations in reasoning paths cannot be effectively verified or rectified. Our solution starts with a key
Through the Lens of Contrast: Self-Improving Visual Reasoning in VLMs
-
cs.AI, q-bio.NC updates on arXiv.org
-
MoltNet: Understanding Social Behavior of AI Agents in the Agent-Native MoltBook
arXiv:2602.13458v1 Announce Type: cross Abstract: Large-scale communities of AI agents are becoming increasingly prevalent, creating new environments for agent-agent social interaction. Prior work has examined multi-agent behavior primarily in controlled or small-scale settings, limiting our understanding of emergent social dynamics at scale. The recent emergence of MoltBook, a social networking platform designed explicitly for AI agents, presents a unique opportunity to study whether and how t